GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (OTCPK:NXSCF) » Definitions » Net Issuance of Preferred Stock

Next Science (Next Science) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Next Science Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Next Science's net issuance of preferred for the six months ended in Dec. 2023 was $0.00 Mil. The number is 0, which means that Next Science has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Next Science's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Next Science Net Issuance of Preferred Stock Historical Data

The historical data trend for Next Science's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Net Issuance of Preferred Stock Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Preferred Stock
Get a 7-Day Free Trial - - - - -

Next Science Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Next Science Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Next Science Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Next Science's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science (Next Science) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (OTCPK:NXSCF) » Definitions » Net Issuance of Preferred Stock
Comparable Companies
ASX:CAN ASX:LGP ASX:ANP ASX:LV1 ASX:IVX ASX:EOF ASX:MVP ASX:ECS ASX:PXS ASX:IDT ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
NXS:Australia
Address
821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067
Website
https://www.nextscience.com
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.